Normal view MARC view ISBD view

Use of Oral Anticoagulants in Patients with Valvular Atrial Fibrillation: Findings From the NCDR PINNACLE Registry R.

MedStar author(s):

Citation: American Heart Journal. 2021 May 22PMID: 34033802Institution: MedStar Heart & Vascular InstituteForm of publication: Journal ArticleMedline article type(s): LetterSubject headings: IN PROCESS -- NOT YET INDEXEDYear: 2021 Local holdings: Available online from MWHC library: 1995 - present, Available in print through MWHC library: 1999 - 2006ISSN:

0002-8703

Name of journal: American heart journalAbstract: Recent data suggest direct oral anticoagulants (DOACs) are as safe and efficacious as warfarin among select patients with valvular heart disease (VHD) and atrial fibrillation (AF). However, real-world treatment patterns of AF stroke prophylaxis in the setting of valvular AF are currently unknown. Accordingly, using the prospective, ambulatory National Cardiovascular Data Registry (NCDR) Practice Innovation and Clinical Excellence (PINNACLE) Registry R, we sought to characterize overall use, temporal trends in use, and the extent of practice-level variation in use of any DOAC and warfarin among patients with valvular AF from January 1, 2013, to March 31, 2019. Copyright (c) 2021. Published by Elsevier Inc.All authors: Bradley SM, Gosch KL, Hess PL, Jani SM, Maddox TM, Michael Ho P, Varosy PD, Virani SSFiscal year: FY2021 Digital Object Identifier:

https://dx.doi.org/10.1016/j.ahj.2021.04.017

Date added to catalog: 2021-06-28

Holdings ( 1 )
Title notes ( 3 )

Holdings
Item type	Current library	Collection	Call number	Status	Date due	Barcode
Journal Article	MedStar Authors Catalog	Article	34033802	Available		34033802

Available online from MWHC library: 1995 - present, Available in print through MWHC library: 1999 - 2006

Recent data suggest direct oral anticoagulants (DOACs) are as safe and efficacious as warfarin among select patients with valvular heart disease (VHD) and atrial fibrillation (AF). However, real-world treatment patterns of AF stroke prophylaxis in the setting of valvular AF are currently unknown. Accordingly, using the prospective, ambulatory National Cardiovascular Data Registry (NCDR) Practice Innovation and Clinical Excellence (PINNACLE) Registry R, we sought to characterize overall use, temporal trends in use, and the extent of practice-level variation in use of any DOAC and warfarin among patients with valvular AF from January 1, 2013, to March 31, 2019. Copyright (c) 2021. Published by Elsevier Inc.

English